<html><head></head><body style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; font-family: Calibri, sans-serif; "><span id="OLK_SRC_BODY_SECTION"><div><div style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); "><div><p class="MsoNormal" align="center" style="font-family: Calibri, sans-serif; font-size: 14px; text-align: center; "><b style="mso-bidi-font-weight:
normal"><i style="mso-bidi-font-style:normal"><span lang="EN-US" style="font-size:18.0pt;font-family:Calibri;mso-bidi-font-family:Arial"><br>Visiting
US Scientist Set to Shake up the Promise of Stem Cell Therapy in Australia?<br></span></i></b><b style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:
normal"><span lang="EN-US" style="font-family:Calibri;mso-bidi-font-family:Arial">-
Cynata Therapeutics new stem cell technology applies to broad range of diseases</span></i></b><b style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span lang="EN-US" style="font-size:14.0pt;font-family:Calibri;mso-bidi-font-family:
Arial">- <o:p></o:p></span></i></b></p><p class="MsoNormal" align="center" style="font-family: Calibri, sans-serif; font-size: 14px; text-align: center; "><b style="mso-bidi-font-weight:
normal"><i style="mso-bidi-font-style:normal"><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;mso-bidi-font-family:Arial"><span style="mso-spacerun:yes"> </span><o:p></o:p></span></i></b></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><b style="mso-bidi-font-weight:normal"><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;mso-bidi-font-family:Arial">SYDNEY,
AUSTRALIA 22 November 2013 –</span></b><span lang="EN-US" style="font-size:
11.0pt;font-family:Calibri;mso-bidi-font-family:Arial"> Internationally recognised
stem cell scientist, Professor Igor Slukvin, Wisconsin University is visiting
Australia as the key-note speaker at a Stem Cell Meeting in Sydney next week.<o:p></o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;
mso-bidi-font-family:Arial"><o:p> </o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;
mso-bidi-font-family:Arial">He will be introducing a revolutionary stem cell
technology to the Australian bioindustry and revealing how it is likely to
shake up the potential of stem cells. <o:p></o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;
mso-bidi-font-family:Arial"><o:p> </o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;
mso-bidi-font-family:Arial">Cymerus<sup>TM</sup>, as the stem cell platformtechnology is called, has the potential to create billions of human stem cells from
a single embryonic stem cell and is extremely important in the therapeutic
application of stem cells for patients.<o:p></o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;
mso-bidi-font-family:Arial"><span style="mso-spacerun:yes"> </span><o:p></o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;
mso-bidi-font-family:Arial">Dr Slukvin came up with the invention in the Wisconsin
laboratory which is well-known for being the home of the world’s first embryonic
stem (ES) cell line made by Professor James Thomson in 1998.<span style="mso-spacerun:yes">  </span><o:p></o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;
mso-bidi-font-family:Arial"><o:p> </o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;
mso-bidi-font-family:Arial">“Stem cell therapy has not taken the path that
scientists predicted over ten years ago,” says Dr Slukvin. Currently, one specific
stem cell type called Mesenchymal stem cell, is showing great promise. Mesenchymal
stem cells works by stimulating the body’s own healing systems.<o:p></o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;
mso-bidi-font-family:Arial"><o:p> </o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;
mso-bidi-font-family:Arial">Cymerus<sup>TM</sup> is able to make masses of
Mesenchymal stem cells that have the potential to remedy a broad range of
diseases including cardiovascular disease, diabetes, diseases of the blood,lung, kidney, eyes teeth and immune system diseases.<o:p></o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;
mso-bidi-font-family:Arial"><br>
Australian biotechnology company, Cynata Therapeutics (ASX:CYP) this week,
renamed and to focus their attention to Cymerus<sup>TM</sup> technology appreciating
the enormous promise it has for stem cell therapeutics. The US company, Cynata Inc.
founded by Professor Slukvin, has just been acquired by the Australian company
to further develop it’s therapeutic application.<o:p></o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;
mso-bidi-font-family:Arial"><o:p> </o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;
mso-bidi-font-family:Arial">Scott Power, Morgan’s healthcare analyst said, “there
is a growing number of biotechnology companies focusing their attention on the
development of stem cell therapeutics.” <o:p></o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;mso-bidi-font-family:Arial"><o:p> </o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;mso-bidi-font-family:Arial">“At the
big end of town is Mesoblast (ASX:MSB) and at the smaller end are biotechs such
as Bionomics, Alchemia (ASX:ACL), Allied Healthcare Group (ASX:AHZ) and Cynata
Therapeutics (ASX:CYP) that are developing stem cells. Also recently, a newstem cell and regeneration company, Regeneus (ASX: RGS) did a successful IPO.”<o:p></o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;mso-bidi-font-family:Arial"><o:p> </o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;
mso-bidi-font-family:Arial">“We are entering a renaissance period in the
biotech sector with healthy investments over the past 6 months into IPO’s and
capital raisings and stem cell is one of the emerging areas,” he said.<o:p></o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;
mso-bidi-font-family:Arial"><o:p> </o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;
mso-bidi-font-family:Arial">The Workshop - <i style="mso-bidi-font-style:normal">Innovating
the Marketplace with Stem<b style="mso-bidi-font-weight:normal"> </b>Cells – </i>on
Friday 29 November will take an in depth look what it will take to push theAustralian stem cell industry forward.It is being hosted by the Stem Cell Network
for biotech investors, analysts, clinicians, scientists, policy makers, IP
lawyers, patient advocates, pharma and biotech executives.<o:p></o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;
mso-bidi-font-family:Arial"><br>
Professor Slukvin will be in Melbourne and Sydney prior to the Stem Cell
Workshop.<o:p></o:p></span></p><p class="MsoPlainText" style="font-family: Calibri, sans-serif; font-size: 14px; "><b style="mso-bidi-font-weight:normal"><u><span style="font-size:11.0pt;font-family:Calibri;mso-bidi-font-family:Calibri;
mso-ansi-language:EN-AU"><o:p><span style="text-decoration:none"> </span></o:p></span></u></b></p><p class="MsoPlainText" style="font-family: Calibri, sans-serif; font-size: 14px; "><b style="mso-bidi-font-weight:normal"><u><span style="font-size:11.0pt;font-family:Calibri;mso-bidi-font-family:Calibri;
mso-ansi-language:EN-AU">MEDIA INVITE: <o:p></o:p></span></u></b></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><b style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:
normal"><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;
mso-bidi-font-family:Arial">19<sup>th</sup> Stem Cell Workshop – Innovating the
Marketplace with Stem Cells –<span style="mso-spacerun:yes">  </span><br>
8:30am-7pm Friday 29 November at Convention Centre, Darling Harbour, Sydney<o:p></o:p></span></i></b></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;
mso-bidi-font-family:Arial">Details: </span><span lang="EN-US"><a href="http://www.stemcellnetwork.org.au/Workshop/MainFrameSet.html"><span style="font-size:11.0pt;font-family:Calibri;mso-bidi-font-family:Arial">http://www.stemcellnetwork.org.au/Workshop/MainFrameSet.html</span></a></span><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;mso-bidi-font-family:
Arial"><o:p></o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;
mso-bidi-font-family:Arial;color:red"><o:p> </o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;
mso-bidi-font-family:Arial">Speakers Include:<o:p></o:p></span></p><ul style="font-family: Calibri, sans-serif; font-size: 14px; margin-top: 0cm; " type="disc">
 <li class="MsoNormal" style="mso-list:l0 level1 lfo1"><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;mso-bidi-font-family:Arial">Prof Igor Slukvin – University of Wisconsin<o:p></o:p></span></li>
 <li class="MsoNormal" style="mso-list:l0 level1 lfo1"><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;mso-bidi-font-family:Arial">Scott     Power – Morgans Ltd. <o:p></o:p></span></li>
 <li class="MsoNormal" style="mso-list:l0 level1 lfo1"><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;mso-bidi-font-family:Arial">Dr
     Uli Schmidt – Genea Biocells<o:p></o:p></span></li>
 <li class="MsoNormal" style="mso-list:l0 level1 lfo1"><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;mso-bidi-font-family:Arial">Professor
     Geoff Symonds - Calimmune<o:p></o:p></span></li>
 <li class="MsoNormal" style="mso-list:l0 level1 lfo1"><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;mso-bidi-font-family:Arial">Dr
     Peter Mountford – Public Systems Innovation<o:p></o:p></span></li></ul><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:11.0pt;font-family:Arial"><o:p> </o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; text-align: justify; "><b><span lang="EN-US" style="font-size:11.0pt;font-family:Arial;text-transform:uppercase">Media
Contact<o:p></o:p></span></b></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; text-align: justify; "><b><span lang="EN-US" style="font-size:11.0pt;font-family:Arial;text-transform:uppercase"><o:p> </o:p></span></b></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><b style="mso-bidi-font-weight:normal"><span style="font-size:11.0pt;font-family:Calibri;mso-fareast-font-family:Calibri;
mso-bidi-font-family:Arial;mso-ansi-language:EN-AU;mso-fareast-language:EN-AU">For
media registration or to arrange interviews:<br>
Daniella Goldberg </span></b><b style="mso-bidi-font-weight:normal"><span style="font-size:10.0pt;font-family:Calibri;mso-fareast-font-family:Calibri;
mso-bidi-font-family:Arial;mso-ansi-language:EN-AU;mso-fareast-language:EN-AU">PhD</span></b><b style="mso-bidi-font-weight:normal"><span style="font-size:11.0pt;font-family:
Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:Arial;mso-ansi-language:
EN-AU;mso-fareast-language:EN-AU">, Gene Genie Media: Tel: 0416 211 067 eml: </span></b><span lang="EN-US"><a href="mailto:Daniella@genegeniemedia.com.au"><b style="mso-bidi-font-weight:
normal"><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;
mso-fareast-font-family:Calibri;mso-bidi-font-family:Arial;mso-ansi-language:
EN-AU;mso-fareast-language:EN-AU"><span lang="EN-US">Daniella@genegeniemedia.com.au</span></span></b></a></span><b style="mso-bidi-font-weight:normal"><span style="font-size:11.0pt;font-family:
Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:Arial;mso-ansi-language:
EN-AU;mso-fareast-language:EN-AU"><o:p></o:p></span></b></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><b style="mso-bidi-font-weight:normal"><span lang="EN-US" style="font-size:11.0pt;
font-family:Calibri;mso-bidi-font-family:Arial">Associate Professor Igor
Slukvin - University of Wisconsin, <span style="mso-spacerun:yes"> </span>Cynata
Therapeutics<o:p></o:p></span></b></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_51" o:spid="_x0000_s1026" type="#_x0000_t75"
 alt="Description: http://www.stemcellnetwork.org.au/Workshop/Images/Slukvin_Igor.jpg"
 style='position:absolute;margin-left:.15pt;margin-top:0;width:46.15pt;
 height:65.15pt;z-index:251659264;visibility:visible;mso-wrap-style:square; mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page'>
 <v:imagedata src="file://localhost/Users/daniella/Library/Caches/TemporaryItems/msoclip/0/clip_image001.jpg"
  o:title="//www.stemcellnetwork.org.au/Workshop/Images/Slukvin_Igor.jpg"/> <w:wrap type="tight"/>
</v:shape><![endif]--><!--[if !vml]--><img width="48" height="67" src="cid:B5F4D484-D481-4A81-A3EF-FD5A8A9D7C4B" align="left" hspace="9" alt="Description: http://www.stemcellnetwork.org.au/Workshop/Images/Slukvin_Igor.jpg" v:shapes="Picture_x0020_51" type="image/png"><!--[endif]--><span lang="EN-US" style="font-size:9.0pt;
font-family:Calibri;mso-bidi-font-family:Arial">Igor Slukvin is Associate
Professor of Pathology and Cell and Regenerative Biology at the University of
Wisconsin-Madison, USA. His research interests focus on development of
hematopoietic, vascular and mesenchymal lineages from human pluripotent stem
cells. He has published more than 70 papers and holds key patents in the area
of hematovascular cell production from human pluripotent stem cells. Dr.
Slukvin is a scientific founder of CDI in the United States and Cynata in
Australia.<o:p></o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><b style="mso-bidi-font-weight:normal"><span style="font-size:11.0pt;font-family:Calibri;mso-fareast-font-family:Calibri;
mso-bidi-font-family:Arial;mso-ansi-language:EN-AU;mso-fareast-language:EN-AU"><o:p> </o:p></span></b></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><b style="mso-bidi-font-weight:normal"><span style="font-size:11.0pt;font-family:Calibri;mso-fareast-font-family:Calibri;
mso-bidi-font-family:Arial;mso-ansi-language:EN-AU;mso-fareast-language:EN-AU">About
Cynata </span></b><b style="mso-bidi-font-weight:normal"><span lang="EN-US" style="font-size:11.0pt;font-family:Calibri;mso-bidi-font-family:Arial">Therapeutics</span></b><b style="mso-bidi-font-weight:normal"><span style="font-size:11.0pt;font-family:
Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:Arial;mso-ansi-language:
EN-AU;mso-fareast-language:EN-AU"><br style="mso-special-character:line-break"><!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break"><!--[endif]--><o:p></o:p></span></b></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:9.0pt;font-family:Calibri;
mso-bidi-font-family:Arial">Cynata Therapeutics Ltd (ASX: CYP) is an Australian
stem cell and regenerative medicine company that is developing a therapeutic
stem cell platform technology, Cymerus™, originating from the University of
Wisconsin-Madison, a world leader in stem cell research.  The proprietary
Cymerus™ technology seeks to address a critical shortcoming in existing methods
of production of mesenchymal stem cells (MSCs) for therapeutic use, which is
the ability to achieve economic manufacture at commercial scale.  Cymerus™
does so through the production of a particular type of MSC precursor, called a
mesenchymoangioblast (MCA).   The Cymerus™ MCA platform provides a
source of MSCs that is independent of donor limitations and provides a
potential “off-the-shelf” stem cell platform for therapeutic product use, with
a pharmaceutical business model and economies of scale.  This has the
potential to create a new standard in the emergent arena of stem cell
therapeutics and provides both a unique differentiator and an important
competitive position. <o:p></o:p></span></p><p class="MsoBodyText" align="left" style="text-align: left; "><font class="Apple-style-span" face="Calibri"><span class="Apple-style-span" style="font-size: 20px;"><br></span></font></p><p class="MsoBodyText" align="left" style="font-family: Calibri, sans-serif; font-size: 14px; text-align: left; "><span lang="EN-US" style="font-size:9.0pt;font-family:Calibri;mso-bidi-font-family:Arial;
mso-ansi-language:EN-US;font-weight:normal"><o:p> </o:p></span></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 14px; "><span lang="EN-US" style="font-size:9.0pt;font-family:Calibri;
mso-bidi-font-family:Arial"><o:p> </o:p></span></p><!--EndFragment--></div><span id="OLK_SRC_BODY_SECTION" style="font-family: Calibri, sans-serif; font-size: 14px; "><div><div style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; font-family: Calibri, sans-serif; "><span id="OLK_SRC_BODY_SECTION"><div><div style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; font-family: Calibri, sans-serif; "><span id="OLK_SRC_BODY_SECTION"><div><div style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; "><span id="OLK_SRC_BODY_SECTION"><div><div style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; "><span id="OLK_SRC_BODY_SECTION"><div><div style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; "><span id="OLK_SRC_BODY_SECTION"><div><div style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; "><span id="OLK_SRC_BODY_SECTION"><div><div style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; "><span id="OLK_SRC_BODY_SECTION"><div><div style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; "><span id="OLK_SRC_BODY_SECTION"><div><div style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; "><span id="OLK_SRC_BODY_SECTION"><div><div style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; "><span id="OLK_SRC_BODY_SECTION"><div><div style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; "><span id="OLK_SRC_BODY_SECTION"><div><div style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; "><div><p class="MsoNormal" style="font-family: Calibri, sans-serif; margin-bottom: 0.0001pt; line-height: normal; "><b style="mso-bidi-font-weight:normal"><span lang="EN-US" style="font-size:10.0pt;mso-ascii-font-family:Calibri;mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:Calibri;mso-bidi-font-family:Arial;
color:black;mso-ansi-language:EN-US;mso-fareast-language:EN-AU">Stem Cell Fact
Sheet:</span></b><b><span lang="X-NONE" style="font-size:10.5pt;mso-ascii-font-family:
Calibri;mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:Calibri;
mso-bidi-font-family:"Times New Roman";color:black;mso-ansi-language:X-NONE;
mso-fareast-language:EN-AU"><o:p></o:p></span></b></p><p class="MsoNormal" style="font-family: Calibri, sans-serif; margin-bottom: 0.0001pt; line-height: normal; "><span lang="EN-US" style="font-size:10.0pt;mso-ascii-font-family:Calibri;
mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:Calibri;
mso-bidi-font-family:Arial;color:black;mso-ansi-language:EN-US;mso-fareast-language:
EN-AU">Stem Cell Therapies and the Cynata Inc Technology (attached)</span></p></div></div></div></span></div></div></span></div></div></span></div></div></span></div></div></span></div></div></span></div></div></span></div></div></span></div></div></span><div style="font-family: Calibri, sans-serif; "><img src="cid:1AC63F63-721F-43D5-8DD1-69496D03D9C2" type="image/png"></div><span id="OLK_SRC_BODY_SECTION" style="font-family: Calibri, sans-serif; "><div><div style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; font-family: Calibri, sans-serif; "><span id="OLK_SRC_BODY_SECTION"><div><div style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; font-family: Calibri, sans-serif; "><span id="OLK_SRC_BODY_SECTION"><div><div style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; font-family: Calibri, sans-serif; "><span id="OLK_SRC_BODY_SECTION"><div><div style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; font-family: Calibri, sans-serif; "><span id="OLK_SRC_BODY_SECTION"><div><div style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; font-family: Calibri, sans-serif; "><span id="OLK_SRC_BODY_SECTION"><div><div style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; font-family: Calibri, sans-serif; "><span id="OLK_SRC_BODY_SECTION"><div><div style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; font-family: Calibri, sans-serif; "><span id="OLK_SRC_BODY_SECTION"><div><div style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; font-family: Calibri, sans-serif; "><span id="OLK_SRC_BODY_SECTION"><div><div style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; font-family: Calibri, sans-serif; "><div><p class="MsoNormal" style="margin-bottom:0cm;margin-bottom:.0001pt;line-height:
normal"><b><span lang="X-NONE" style="font-size:10.5pt;mso-ascii-font-family:Calibri;mso-fareast-font-family:
"Times New Roman";mso-hansi-font-family:Calibri;mso-bidi-font-family:"Times New Roman";
color:black;mso-ansi-language:X-NONE;mso-fareast-language:EN-AU"><o:p></o:p></span></b></p><p class="MsoNormal" style="margin-bottom:0cm;margin-bottom:.0001pt;line-height:
normal"><span lang="EN-US" style="font-size:9.0pt;mso-ascii-font-family:Calibri;
mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:Calibri;
mso-bidi-font-family:Arial;color:black;mso-ansi-language:EN-US;mso-fareast-language:
EN-AU"> </span><b><span lang="X-NONE" style="font-size:10.5pt;mso-ascii-font-family:
Calibri;mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:Calibri;
mso-bidi-font-family:"Times New Roman";color:black;mso-ansi-language:X-NONE;
mso-fareast-language:EN-AU"><o:p></o:p></span></b></p><p class="MsoNormal" style="margin-bottom:0cm;margin-bottom:.0001pt;line-height:
normal"><span lang="EN-US" style="font-size:9.0pt;mso-ascii-font-family:Calibri;
mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:Calibri;
mso-bidi-font-family:Arial;color:black;mso-ansi-language:EN-US;mso-fareast-language:
EN-AU"> </span><b><span lang="X-NONE" style="font-size:10.5pt;mso-ascii-font-family:
Calibri;mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:Calibri;
mso-bidi-font-family:"Times New Roman";color:black;mso-ansi-language:X-NONE;
mso-fareast-language:EN-AU"><o:p></o:p></span></b></p><p class="MsoNormal"><o:p> </o:p></p><!--EndFragment--></div></div></div></span></div></div></span></div></div></span></div></div></span></div></div></span></div></div></span></div></div></span></div></div></span></div></div></span></div></div></span></div></div></span></div></div></span></div></div></span></body></html>